Strategy Means Nothing If Execution Is Not Aligned

Sarah Sink
Feb 19
3 min read

Every program starts with a strategy.

Clear timelines.

Defined milestones.

Commercial goals.

A vision for how the product reaches patients.

On paper, strategy is rarely the problem.

The challenge shows up when execution begins.

Development teams focus on science. Manufacturing teams focus on scalability. Quality focuses on compliance. Fill-finish teams focus on aseptic risk and supply continuity. Each function is doing the right thing, but often through a different lens.

When those perspectives are not aligned, strategy slowly separates from execution.

Why Alignment Breaks Down

Alignment does not usually fail because people disagree. It fails because assumptions go unspoken.

Development assumes manufacturing can easily scale the process. Manufacturing assumes analytical methods are fully ready. Fill-finish teams assume formulation and container decisions are stable. Commercial teams assume timelines will hold.

None of these assumptions are unreasonable. The issue is that they are rarely validated together.

As programs move forward, small gaps compound. Teams begin solving different problems instead of the same one.

That is when strategy starts to feel disconnected from reality.

Where Misalignment Shows Up First

Misalignment often appears during transitions.

The move from development into GMP manufacturing.Tech transfer between sites.Preparing for sterile fill finish.Scaling for clinical or commercial supply.

These moments require cross-functional clarity. If alignment has not been built early, teams spend time reworking decisions rather than executing them.

Timelines stretch. Confidence drops. Friction increases.

The science may still be strong, but execution becomes harder than it should be.

Sterile Fill Finish Is the Ultimate Alignment Test

Sterile fill finish tends to expose misalignment faster than any other stage.

Container closure decisions, filtration strategies, fill volumes, hold times, and line scheduling all depend on upstream choices being stable and clearly communicated.

When fill-finish teams are brought in late, they often discover constraints that require upstream adjustments. Those changes can ripple backward into manufacturing or analytical work, creating unexpected delays.

Programs that include fill-finish thinking early avoid these surprises. They align decisions before execution pressure increases.

Fill finish should not be treated as the final step. It should be part of the strategy from the beginning.

The Role of CDMO Partnerships

Alignment does not happen automatically, especially when multiple organizations are involved.

Strong CDMO partnerships create alignment by:

Encouraging early SME collaboration
Clarifying ownership and decision-making
Sharing risk transparently
Connecting development choices to downstream execution

From a business development perspective, this is one of the most important differentiators between partnerships that feel smooth and those that feel reactive.

The best partners are not simply executing tasks. They are aligning strategy with reality.

Why Business Development Plays a Critical Role

Business development professionals sit at a unique intersection.

They understand sponsor expectations. They understand operational realities. They see how early decisions shape downstream execution.

Strong BD professionals help align conversations early. They ask questions that connect development plans to manufacturing and fill-finish realities. They ensure that commitments made during proposals can actually be delivered during execution.

This is not about being conservative. It is about being credible.

Alignment starts long before the first batch is manufactured.

What Strong Programs Do Differently

Programs that maintain alignment across the lifecycle tend to share a few habits:

They involve cross-functional SMEs early
They connect strategy to execution at every transition
They include fill-finish considerations from the start
They revisit assumptions as programs evolve
They communicate openly when reality changes

These programs move faster because teams are working toward the same outcome.

Final Thoughts

Strategy is important, but execution is what determines success.

In development, manufacturing, and sterile fill finish, alignment is what keeps programs moving forward when complexity increases.

If your team is evaluating CDMOs or comparing proposals, it is worth looking beyond capabilities and timelines to ask how partners create alignment across the full lifecycle.

My guide, How to Compare CDMO Quotes: 10 Factors Beyond Cost helps biotech teams evaluate not just what a partner can do, but how well they can execute alongside you as programs evolve.

Because strategy only works when execution is aligned.

For more insights and personalized support in navigating the biotech-CDMO landscape, visit www.yourpharmagirl.com and follow Your Pharma Girl on LinkedIn. Whether you need strategic guidance, tailored business development solutions, or expert advice on building lasting partnerships, I am here to help you and your team succeed at every stage of development.